MHCII (Major Histocompatibility Complex Class II) represents a pivotal immunological node bridging innate and adaptive immunity. Primarily expressed on professional antigen-presenting cells (APCs), MHCII molecules present exogenous peptides to CD4+ T helper cells, orchestrating immune responses in both oncology and autoimmune contexts.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MHCII drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MHCII (HLA-DR/DQ/DP) Heterodimer Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed. |
View MHCII Products |
| Gene Delivery | MHCII Promise-ORF / Lentivirus Full-length ORF (Alpha and Beta chains) for stable cell lines. |
View MHCII Products |
| Benchmark Ab | Anti-MHCII Recombinant Antibody (Clone L243) Recombinant positive control for binding and blocking assays. |
View MHCII Products |
| Validator | MHCII siRNA Set For knockdown verification in APCs. |
View MHCII Products |
| Related Target A | LAG3 Primary immune checkpoint receptor that binds MHCII to inhibit T cell activation. |
View LAG3 Products |
| Related Target B | CD4 Co-receptor on T helper cells interacting with MHCII to facilitate TCR signaling. |
View CD4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Heterodimer Stability (Alpha/Beta pairing) | Co-expressed HLA-DRA/DRB heterodimers stabilized via rational linker design; sequence verified. |
| Polymorphism & Allele Specificity | Diverse HLA-DR, HLA-DQ, and HLA-DP allele-specific proteins strictly verified by mass spectrometry. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) and reference clones (e.g., L243) included. |
| False Positives | Validated siRNA included for target-specific knockdown and specificity checks. |
Live MHCII R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MHCII therapeutics is intensifying, with major players shifting focus from traditional global immunosuppression to antigen-specific tolerogenic therapies and immune checkpoint modulation. As first-generation LAG-3/MHCII blockade therapies reach the clinic, the next wave of R&D is targeting allele-specific MHCII blockers for autoimmune diseases and bispecific antibodies to selectively modulate antigen presentation in the tumor microenvironment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | Immutep, Bristol Myers Squibb | Solid Tumors, Autoimmune Diseases | Blocking Assay (Need stable HLA-DR/DQ heterodimers to test LAG-3 or TCR disruption) |
| Tolerogenic Antigen Therapies | Anokion, Cour Pharmaceutical | Celiac Disease, Multiple Sclerosis | Peptide-Loading & HLA Binding Assays (Need empty or peptide-receptive recombinant MHCII) |
| Bispecific Modalities | Roche, AstraZeneca | Oncology, Immune Disorders | Selectivity Assay (Need Mutant vs WT Proteins and cell lines expressing specific MHCII alleles) |